Guardian begins clinical tests of 3i technology for Medical applications

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Guardian Technologies International Inc. yesterday announced an agreement to put its 3i technology — developed originally as a homeland security application — in clinical tests to evaluate its potential as a medical application. The test will be undertaken by Dr. H.K. Huang at the Medical Imaging and Informatics Laboratory (IPI) at the Keck School of Medicine, University of Southern California to do clinical testing on its 3i technology.

Huang will conduct a multiple-phase process to clinically evaluate, and provide feedback on potential enhancements, to Guardian's 3i intelligent imaging analysis solutions as applied to medical radiology imaging. Guardian has stated that many of the core features and capabilities deployed for its security products can be utilized for clinical radiology applications. Guardian considers 3i ideally suited for many types of imaging applications in medical radiology.

"3i is very effective at segmenting, clarifying, distinguishing, and identifying organic objects, even when they are masked by one or more other objects of similar density and chemical composition. As with explosives, the human body is made of organic compounds. Therefore, it is a natural extension of the technology to adapt the scientific principles employed for explosives detection to medical image analysis," said Richard Borrelli, vice president of Business Development – Healthcare, Guardian. "Our product development direction will be focused on the areas of greatest clinical need; finding the best pairing of our 3i-based computer-aided detection technologies with the major challenges in clinical imaging."

In regards to the upcoming trials, Huang stated that "based on their complex nature and the challenges inherent in imaging and interpretation, we have selected for evaluation what we believe are the three key clinical areas - breast, lungs, and brain,  Bringing a technological capability, such as 3i, to these critical challenges will produce major benefits for improved detection and better patient outcomes."